CN104491546A - Application of pharmaceutical composition in preparation of medicine for treating wind-warm lung-heat disease - Google Patents
Application of pharmaceutical composition in preparation of medicine for treating wind-warm lung-heat disease Download PDFInfo
- Publication number
- CN104491546A CN104491546A CN201410821866.9A CN201410821866A CN104491546A CN 104491546 A CN104491546 A CN 104491546A CN 201410821866 A CN201410821866 A CN 201410821866A CN 104491546 A CN104491546 A CN 104491546A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- heat
- lung
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines and in particular relates to an application of a pharmaceutical composition in preparation of a medicine for treating wind-warm lung-heat disease. The pharmaceutical composition comprises the following components: isatis root, rhizoma anemarrhenae, sweet wormwood, fructus forsythiae, the root bark of white mulberry, stiff silkworm, coptis chinensis, hawthorns, rhizoma phragmitis and liquorice. The pharmaceutical composition disclosed by the invention has the effects of clearing away heat and toxic materials and ventilating the lung and resolving phlegm, is exact in curative effect on wind-warm lung-heat disease, particularly phlegm-heat obstructing lung type wind-warm lung-heat disease and is suitable for clinical popularization and application.
Description
Technical field
The invention belongs to medical art, be specifically related to the purposes of a kind of pharmaceutical composition in preparation treatment wind-warm lung-heat medicine.
Background technology
Wind-warm lung-heat disease violates lung by wind heat pathogenic factor, and heat stops up lung qi, and caused by impairment of purifying function of the lung, to generate heat, cough, chest pain etc. are main clinical manifestation.Be equivalent to Acute Lung inflammatory lesion.Belonging to tcm internal medicine exogenous disease research field, is commonly encountered diseases and the frequently-occurring disease of tcm internal medicine.
Community acquired pneumonia (community acquired pneumonia, CAP) refer to infectious pulmonary parenchyma (containing alveolar wall and the sensu lato interstitial lung) inflammation suffered from outside hospital, comprise and there is clearly preclinical pathogenic infection and the pneumonia of falling ill in average latency after being admitted to hospital.Motherland's medical science think community acquired pneumonia among old persons belong to more Chinese medicine " wind-warm lung-heat ", " cough " sick category.
Current western medicine there is no specific treatment method clinically, still mainly adopt second and third cephalosporin in generation, beta-lactam class, fluoroquinolones is treated, though there is certain curative effect, along with the transition of pathogenic microorganism, drug resistance phenomenon is on the rise, and side effect is larger, some drugs is expensive, therefore be difficult to popularity, and being rationally applied in of Chinese medicine is brought down a fever and is eliminated pulmonary infiltrates sexually transmitted disease (STD) fast and become and delay insufficiency of pulmonary function aspect and have the incomparable advantage of doctor trained in Western medicine, the Chinese medicine composition therefore studying effective treatment wind-warm lung-heat disease is very necessary.
Summary of the invention
The invention provides the purposes of a kind of pharmaceutical composition in preparation treatment wind-warm lung-heat medicine, this pharmaceutical composition is rapid-action, good effect, toxic and side effects is little, and it is obtained by following raw material: Radix Isatidis, the Rhizoma Anemarrhenae, Herba Artemisiae Annuae, Fructus Forsythiae, Cortex Mori, Bombyx Batryticatus, Rhizoma Coptidis, Fructus Crataegi, Rhizoma Phragmitis, Radix Glycyrrhizae.
In pharmaceutical composition of the present invention, described Radix Isatidis is bitter, cold.Return liver; Stomach warp.Heat clearing away, removing toxic substances, removing heat from blood, sore-throat relieving.Maculae caused by violent heat pathogen; High heat headache; Major part pestilence; Crimson tongue is purple dark, scarlet fever; Erysipelas; Mumps; Sore throat; Skin ulcer is swollen, carbuncle; Chickenpox; Measles; Influenza.
The Rhizoma Anemarrhenae, bitter, sweet, cold.Return lung, stomach, kidney channel.Clearing away heat-fire, promotes the production of body fluid and moisturizes.For fever caused by exogenous pathogenic factors, high hot excessive thirst, lung-heat type cough, osteopyrexia and fever, interior-heat is quenched one's thirst, dryness of the intestine constipation.
Herba Artemisiae Annuae, bitter, acrid, cold.Return liver, gallbladder meridian.Clearing away summer-heat, except steaming, preventing the attack (or recurrence) of malaria.For pathogenic summer-heat heating, fever due to yin deficiency, night fever abating at dawn, hectic fever due to YIN-deficiency consumptive fever, malaria cold and heat, jaundice due to damp-heat.
Fructus Forsythiae, bitter, be slightly cold.Return lung, the heart, small intestine meridian.Heat-clearing and toxic substances removing, dispersing swelling and dissipating binds.For carbuncle, scrofula, acute mastitis, erysipelas, anemopyretic cold, epidemic febrile disease from the beginning of, warmly join the army, high hot excessive thirst, coma sends out speckle, pyretic stranguria urine retention.
Cortex Mori, sweet, cold.Return lung meridian.Eliminating pathogen from the lung for relieving asthma, inducing diuresis to remove edema.For dyspnea and cough due to lung-heat, edema distension oliguria, appearance skin edema.
Bombyx Batryticatus, salty, pungent, flat.Return liver, lung, stomach warp.Expelling wind for relieving convulsion, dissipating phlegm and resolving masses.For convulsion with spasms, laryngopharynx swelling and pain, skin pruritus, submandibular lymph nodes is scorching, facial paralysis.
Rhizoma Coptidis, bitter, cold.GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel.Heat clearing and damp drying, eliminating fire and detoxication.For damp and hot feeling of fullness, vomiting acid regurgitation, dysentery, jaundice, unconsciousness due to high fever, hyperactivity of heart-fire, dysphoria and insomnia, heat in blood tells nosebleed, conjunctival congestion, and toothache, quenches one's thirst, carbuncle furuncle.
Fructus Crataegi, sweet in the mouth, slightly warm in nature, acid.Enter spleen, stomach, Liver Channel; There is promoting digestion and invigorating the stomach, blood circulation promoting and blood stasis dispelling, effect of anthelmintic; Cure mainly meat stagnation, gastral cavilty is suffered from abdominal pain, blood stasis amenorrhea, postpartum stagnation, trusted subordinate's twinge, hernia pain, hyperlipidemia etc.
Rhizoma Phragmitis, sweet, cold.Attach to the lung and stomach meridians.Clearing away heat and promoting production of body fluid, relieving restlessness, preventing or arresting vomiting, diuresis.For calentura excessive thirst, gastric heat is vomitted the sound of vomiting, cough due to lung-heat, lung abscess vomiting pus, the puckery pain of pyretic stranguria.
Radix Glycyrrhizae, sweet, flat.GUIXIN, lung, spleen, stomach warp.Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, the anxious pain of gastral cavity abdomen, extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
Pharmaceutical composition of the present invention selects Radix Isatidis and the Rhizoma Anemarrhenae, heat-clearing and toxic substances removing, promotes the production of body fluid and moisturizes.Herba Artemisiae Annuae, Fructus Forsythiae, Cortex Mori, strengthen the effect of heat-clearing and toxic substances removing.Bombyx Batryticatus, Rhizoma Coptidis, Fructus Crataegi clearing away lung-heat, reason lung qi, supports lung yin.Rhizoma Phragmitis, Radix Glycyrrhizae, for making medicine, have benefiting vital QI for tranquillizing, coordinating the actions of various ingredients in a prescription, help the effect of heat-clearing and toxic substances removing.
The technical scheme adopted for solving its technical problem is the pharmaceutical composition of described treatment wind-warm lung-heat disease, be made up of the medicine material of following weight: Radix Isatidis 14-26 part, Rhizoma Anemarrhenae 14-26 part, Artemisia annua L. 4-16 part, Fructus Forsythiae 4-16 part, Cortex Mori 9-21 part, Bombyx Batryticatus 4-11 part, Rhizoma Coptidis 7-17 part, Fructus Crataegi 4-16 part, Rhizoma Phragmitis 4-11 part, Radix Glycyrrhizae 3-9 part.
The preferred technical solution of the present invention is, described pharmaceutical composition of the present invention is obtained by the raw material of following weight portion: Radix Isatidis 20 parts, the Rhizoma Anemarrhenae 20 parts, Artemisia annua L. 10 parts, Fructus Forsythiae 10 parts, Cortex Mori 15 parts, Bombyx Batryticatus 8 parts, Rhizoma Coptidis 12 parts, Fructus Crataegi 10 parts, Rhizoma Phragmitis 7 parts, 6 parts, Radix Glycyrrhizae.
Present invention also offers the preparation method of described pharmaceutical composition, after specifically comprising the steps: that the raw material Radix Isatidis of above-mentioned weight portion, the Rhizoma Anemarrhenae, Herba Artemisiae Annuae, Fructus Forsythiae, Cortex Mori, Bombyx Batryticatus, Rhizoma Coptidis, Fructus Crataegi, Rhizoma Phragmitis, Radix Glycyrrhizae powder are broken into fine powder, after adding the water soaking 30min of medical material gross weight 5 times amount, decoct 2.5 hours, filter cleaner extracting juice, when filtrate being concentrated into 75 DEG C, its relative density is the thick paste of 1.01-1.05, to obtain final product.
Those skilled in the art directly can be used as medicine on obtained active constituents of medicine basis of the present invention to use or add on pharmaceutics acceptable adjuvant routinely technique be prepared into required preparation.As the oral drugs of the solid dosage form such as conventional tablet (dispersible tablet, effervescent tablet, oral cavity disintegration tablet, buccal tablet, chewable tablet, effervescent tablet), capsule (hard capsule, soft capsule), granule, pill (drop pill), powder can be made, the oral drugs of the liquid forms such as syrup, oral liquid, water preparation, mixture, decoction also can be made.Therefore, in this pharmaceutical composition except effective ingredient, pharmaceutically acceptable adjuvant can also be contained.Preferably, pharmaceutical composition of the present invention conveniently preparation technology be prepared into oral liquid, syrup, capsule or powder etc.
The present invention also asks to protect the purposes of aforementioned pharmaceutical compositions in preparation treatment phlegm-heat obstructing lung type wind-warm lung-heat medicine.Known by clinical trial, patient treatment is efficacy evaluation result after 2 weeks, and symptom, sign aspect cure rate are 35.0%, improvement rate 65.0%, effective percentage 100%.According to the change of chest imaging (x-ray) result, evaluate the effect for the treatment of.Result shows: clinical recovery 14 example, effective 19 examples, and effective 7 examples, have no improvement 0 example.In safety evaluatio, during treatment group patient consumes, do not find obvious exception and serious adverse reaction.Illustrate that using medicine composite for curing wind-warm lung-heat disease of the present invention particularly to treat belongs to phlegm-heat obstructing lung type wind-warm lung-heat disease determined curative effect thus, safe and reliable, serve the remarkable result for the treatment of both the principal and secondary aspects of a disease, can be used as the effective ways for the treatment of phlegm-heat obstructing lung type wind-warm lung-heat disease, be worth of widely use in clinical.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to following specific embodiment.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
embodiment 1
The each raw material of the present invention is taken: Radix Isatidis 15 parts, the Rhizoma Anemarrhenae 15 parts, Artemisia annua L. 5 parts, Fructus Forsythiae 5 parts, Cortex Mori 10 parts, Bombyx Batryticatus 5 parts, Rhizoma Coptidis 8 parts, Fructus Crataegi 5 parts, Rhizoma Phragmitis 5 parts, 4 parts, Radix Glycyrrhizae by following weight portion.
embodiment 2
The each raw material of the present invention is taken: Radix Isatidis 25 parts, the Rhizoma Anemarrhenae 25 parts, Artemisia annua L. 15 parts, Fructus Forsythiae 15 parts, Cortex Mori 20 parts, Bombyx Batryticatus 10 parts, Rhizoma Coptidis 16 parts, Fructus Crataegi 15 parts, Rhizoma Phragmitis 10 parts, 8 parts, Radix Glycyrrhizae by following weight portion.
embodiment 3
The each raw material of the present invention is taken: Radix Isatidis 15 parts, the Rhizoma Anemarrhenae 15 parts, Artemisia annua L. 5 parts, Fructus Forsythiae 5 parts, Cortex Mori 10 parts, Bombyx Batryticatus 10 parts, Rhizoma Coptidis 16 parts, Fructus Crataegi 15 parts, Rhizoma Phragmitis 10 parts, 8 parts, Radix Glycyrrhizae by following weight portion.
embodiment 4
The each raw material of the present invention is taken: Radix Isatidis 25 parts, the Rhizoma Anemarrhenae 25 parts, Artemisia annua L. 15 parts, Fructus Forsythiae 15 parts, Cortex Mori 20 parts, Bombyx Batryticatus 5 parts, Rhizoma Coptidis 8 parts, Fructus Crataegi 5 parts, Rhizoma Phragmitis 5 parts, 4 parts, Radix Glycyrrhizae by following weight portion.
embodiment 5
The each raw material of the present invention is taken: Radix Isatidis 20 parts, the Rhizoma Anemarrhenae 20 parts, Artemisia annua L. 10 parts, Fructus Forsythiae 10 parts, Cortex Mori 15 parts, Bombyx Batryticatus 8 parts, Rhizoma Coptidis 12 parts, Fructus Crataegi 10 parts, Rhizoma Phragmitis 7 parts, 6 parts, Radix Glycyrrhizae by following weight portion.
The preparation technology of embodiment 1-5 is as follows: after the raw material Radix Isatidis of above-mentioned weight portion, the Rhizoma Anemarrhenae, Herba Artemisiae Annuae, Fructus Forsythiae, Cortex Mori, Bombyx Batryticatus, Rhizoma Coptidis, Fructus Crataegi, Rhizoma Phragmitis, Radix Glycyrrhizae being pulverized, after adding the water soaking 30min of gross weight 5 times amount, decoct 2.5 hours, filter cleaner extracting juice, when filtrate being concentrated into 75 DEG C, its relative density is the thick paste of 1.01-1.05, to obtain final product.Those skilled in the art directly can be used as medicine on this basis and be used or add adjuvant conventional formulation technique and obtain the conventional oral formulations such as oral liquid, water preparation, electuary, capsule or powder.
When using medicine composite for curing wind-warm lung-heat disease of the present invention, take prepared oral liquid, every bottle contains crude drug amount 10g, each 1 bottle, 2 times on the one.Take prepared electuary or powder, every bag contains crude drug amount 5g, each 2 bags, 2 times on the one.
the clinical observation of embodiment 6 medicine composite for curing wind-warm lung-heat disease of the present invention
1, case-data: patient 40 example meeting wind-warm lung-heat disease (syndrome of phlegm-heat obstructing lung) diagnostic criteria selecting hospital ward and outpatient clinic.
In select 40 routine clinical cases, include in 40 routine patients, age 61-84 year, 74 years old mean age, mild 19 example, middle disease 21 example.
2, diagnosis basis:
1) the tcm diagnosis standard of wind-warm lung-heat disease
(1) with fever of the body, cough, excessive thirst, or out of breath, chest pain is accompanied to be primary symptom.
(2) the visible high fever of sick severe one, Blushing, dysphoria, unconsciousness and delirium, or the disease such as extreme cold of the limbs.
(3) winter and spring is more.Have the advantages that onset is anxious, the change of disease is fast, the course of disease is short.
(4) blood leukocytes sum and neutrophilic granulocyte rising person, belong to bacterial infection; Person normal or on the low side is based on viral infection.
(5) there is consolidation sign in pulmonary, or audible and dry moist rale.
(6) sputum direct smear or cultivation can find pathogen.
(7) fluoroscopy of chest or take the photograph sheet, the visible one or both sides lobe of the lung or lung section inflammatory shade.
2) TCM syndrome diagnostic criteria:
Phlegm-heat obstructing in the lung: fever of the body excessive thirst, sweating, coughs rough, or expectorant fulminant leucorrhagia with yellowish discharge blood, and feeling of oppression and pain in the chest is thirsty.Red tongue with yellow fur, full and rapid pulse or sliding number.
3) Western medicine diagnose standard: Western medicine diagnose standard is formulated with reference to respirology branch 2006 of Chinese Medical Association " Community-Acquired Pneumonia and treatment guidelines ".Clinical diagnosis foundation:
L cough that () occurs recently, expectoration or original symptoms of respiratory disease increase the weight of, and occur purulent sputum, accompany or do not accompany chest pain;
(2) generate heat;
(3) pulmonary consolidation sign and (or) news and moist sound of trembling;
(4) WBC > 10 × 10
9/ L or < 4 × 10
9/ L, companion or not companion cell shift to left;
(5) chest X-ray display lamellar, patch shape wellability shade or chromic fibrous change, accompany or do not accompany hydrothorax;
Above in the item of (l)-(4) any 1 add the 5th, and except pulmonary tuberculosis, lung tumors, non-infectious Interstitial Lung Disease, pulmonary edema, pulmonary atelectasis, pulmonary infarction, after pulmanory eosinophilia and pulmonary vasculitis etc., can clinical diagnosis be set up.
4) severity Scaling standard
(l) mild pneumonia: meet following 4 persons, mild pneumonia can be diagnosed as:
1. body temperature is lower than 38 DEG C;
2. respiratory function or arterial blood gas measure normal or compare with basic value without worsening;
3. leukocyte is lower than 10 × 10
9/ L;
4. without other complication.
(2) severe pneumonia: possessing in following sign 1 or more person diagnosable is severe pneumonia:
1. disturbance of consciousness;
2. respiratory frequency >=30/min;
3. PaO
2< 60mmHg, PaO
2/ FiO
2< 300, needs row Failure Treated with Mechanical Ventilation;
4. systolic arterial pressure < 90mmHg;
5. concurrent septic shock;
6. x-ray chest films showed bilateral or leafyly to get involved, or in the 48h that is admitted to hospital, pathological changes expands >=50%;
7. oliguria: urine volume < 20mL/h, or < 80mL/4h, or Complicated With Acute Renal Failure needs dialysis treatment.
(3) disease pneumonia in: the state of an illness is person between mild pneumonia and severe pneumonia.
3, inclusive criteria:
(1) age is between 60-85 year;
(2) meet the traditional Chinese medical science and disease, Western medicine diagnose standard, and belong to mild pneumonia or middle disease patients with pneumonia;
(3) " Informed Consent Form " person is signed.
4, exclusion standard:
(1) " Informed Consent Form " person is not signed.
(2) merge intentionally, liver, serious disease and the insane such as kidney and coagulation disorders.
(3) diabetic nephropathy patient.
(4) gestation, preparation gestation or women breast-feeding their children, or have drug allergy history person.
(5) pulmonary is because of other diseases, as chronic obstructive pulmonary disease, active tuberculosis, lung tumors, non-infectious Interstitial Lung Disease, pulmonary edema, pulmonary atelectasis, pulmonary infarction, pulmanory eosinophilia and pulmonary vasculitis are admitted to hospital and Complicating Pneumonia In Patients person.
(6) patient of other drug clinical trial is being participated in.
(7) known maybe may to trial drug and component allergy sufferers thereof.
5, to reject and the standard that comes off:
(1), after case is selected in, find not meet inclusive criteria or meet exclusion standard person;
(2) there is serious adverse events, judge to stop this case clinical trial person according to doctor;
(3) case selected after data not entirely or not by specifying medication person;
(4) in process of the test, experimenter's compliance is poor, and affect the treatment estimator.
6, usage and dosage:
Patient gives Drug therapy of the present invention, electuary prepared by Example 5, and every bag, containing crude drug amount 5g, each 2 bags, 2 times on the one, is used in conjunction 2 weeks.
7, efficacy evaluation:
(1) cure: symptom and sign disappear, laboratory and x-ray etc. inspections recover normal.
(2) take a turn for the better: symptom and sign, lab testing etc. make moderate progress, x-ray checks that pulmonary lesions absorbs not yet completely.
(3) do not heal: the state of an illness has no improvement.
8, chest imaging (x-ray) is evaluated:
(1) clinical recovery: the whole absorber of chest x-ray inflammation.
(2) effective: the large portion absorber of chest x-ray inflammation.
(3) effective: chest x-ray inflammatory components absorber.
(4) invalid: chest x-ray inflammation is without obviously change or enlarger.
9, therapeutic effect:
Without rejecting and the case that comes off in therapeutic process, all complete clinical observation.
Patient treatment is efficacy evaluation result after 2 weeks, and symptom, sign aspect cure rate are 35.0%, improvement rate 65.0%, effective percentage 100%.
According to the change of chest imaging (x-ray) result, evaluate the effect for the treatment of.Result shows: clinical recovery 14 example, effective 19 examples, and effective 7 examples, have no improvement 0 example.
In safety evaluatio, there is not obvious toxic-side effects and serious adverse reaction in the front and back clinical observation patient that takes medicine (hepatic and renal function, routine urinalysis, electrocardiogram).
Thus illustrate use medicine composite for curing wind-warm lung-heat disease of the present invention particularly treat belong to phlegm-heat obstructing lung type wind-warm lung-heat disease medicine card conform to, curative effect is obvious, safe and reliable, can be used as the effective ways for the treatment of phlegm-heat obstructing lung type wind-warm lung-heat disease, be worth of widely use in clinical.
Claims (7)
1. the purposes of a pharmaceutical composition in preparation treatment wind-warm lung-heat medicine, it is characterized in that, described pharmaceutical composition is obtained by the raw material of following weight portion: Radix Isatidis 14-26 part, Rhizoma Anemarrhenae 14-26 part, Artemisia annua L. 4-16 part, Fructus Forsythiae 4-16 part, Cortex Mori 9-21 part, Bombyx Batryticatus 4-11 part, Rhizoma Coptidis 7-17 part, Fructus Crataegi 4-16 part, Rhizoma Phragmitis 4-11 part, Radix Glycyrrhizae 3-9 part.
2. purposes as claimed in claim 1, it is characterized in that, described pharmaceutical composition is obtained by the raw material of following weight portion: Radix Isatidis 20 parts, the Rhizoma Anemarrhenae 20 parts, Artemisia annua L. 10 parts, Fructus Forsythiae 10 parts, Cortex Mori 15 parts, Bombyx Batryticatus 8 parts, Rhizoma Coptidis 12 parts, Fructus Crataegi 10 parts, Rhizoma Phragmitis 7 parts, 6 parts, Radix Glycyrrhizae.
3. purposes as claimed in claim 1 or 2, it is characterized in that, described pharmaceutical composition is oral formulations.
4. purposes as claimed in claim 3, it is characterized in that, described oral formulations is oral liquid, water preparation, electuary, capsule or powder.
5. purposes as claimed in claim 4, it is characterized in that, described oral formulations is electuary.
6. purposes as claimed in claim 1 or 2, it is characterized in that, the preparation method of described pharmaceutical composition comprises the steps: after the raw material Radix Isatidis of above-mentioned weight portion, the Rhizoma Anemarrhenae, Herba Artemisiae Annuae, Fructus Forsythiae, Cortex Mori, Bombyx Batryticatus, Rhizoma Coptidis, Fructus Crataegi, Rhizoma Phragmitis, Radix Glycyrrhizae pulverizing, after adding the water soaking 30min of medical material gross weight 5 times amount, decoct 2.5 hours, filter cleaner extracting juice, when being concentrated into 75 DEG C by filtrate, its relative density is the thick paste of 1.01-1.05, to obtain final product.
7. purposes as claimed in claim 1 or 2, is characterized in that, the purposes of described pharmaceutical composition in preparation treatment phlegm-heat obstructing lung type wind-warm lung-heat medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410821866.9A CN104491546A (en) | 2014-12-26 | 2014-12-26 | Application of pharmaceutical composition in preparation of medicine for treating wind-warm lung-heat disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410821866.9A CN104491546A (en) | 2014-12-26 | 2014-12-26 | Application of pharmaceutical composition in preparation of medicine for treating wind-warm lung-heat disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104491546A true CN104491546A (en) | 2015-04-08 |
Family
ID=52933060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410821866.9A Pending CN104491546A (en) | 2014-12-26 | 2014-12-26 | Application of pharmaceutical composition in preparation of medicine for treating wind-warm lung-heat disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104491546A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031359A (en) * | 2015-08-25 | 2015-11-11 | 山东省农业科学院畜牧兽医研究所 | Vinegar drink capable of clearing away lung heat and promoting blood circulation and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007210922A (en) * | 2006-02-08 | 2007-08-23 | Kitasato Gakuen | Oral composition |
| CN101601830A (en) * | 2009-07-10 | 2009-12-16 | 卢速江 | A kind of Chinese medicine preparation for the treatment of flu and preparation method thereof |
| CN102068667A (en) * | 2009-11-19 | 2011-05-25 | 史海霞 | Chinese medicine composition with clearing heat and detoxicating functions |
| CN102973854A (en) * | 2011-09-05 | 2013-03-20 | 魏加珍 | Chinese patent medicine granules for treating cold |
-
2014
- 2014-12-26 CN CN201410821866.9A patent/CN104491546A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007210922A (en) * | 2006-02-08 | 2007-08-23 | Kitasato Gakuen | Oral composition |
| CN101601830A (en) * | 2009-07-10 | 2009-12-16 | 卢速江 | A kind of Chinese medicine preparation for the treatment of flu and preparation method thereof |
| CN102068667A (en) * | 2009-11-19 | 2011-05-25 | 史海霞 | Chinese medicine composition with clearing heat and detoxicating functions |
| CN102973854A (en) * | 2011-09-05 | 2013-03-20 | 魏加珍 | Chinese patent medicine granules for treating cold |
Non-Patent Citations (4)
| Title |
|---|
| ***: "《中医药学概论》", 31 January 2009, 济南出版社 * |
| 张永华等: "《常见内科疾病中西医结合诊疗思路》", 30 April 2010, 中医古籍出版社 * |
| 范淑惠: "知石清解针剂治疗风温肺热病20例", 《陕西中医》 * |
| 郑秀丽: "张之文教授辨治咳嗽验案3则", 《江苏中医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031359A (en) * | 2015-08-25 | 2015-11-11 | 山东省农业科学院畜牧兽医研究所 | Vinegar drink capable of clearing away lung heat and promoting blood circulation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN103169862A (en) | Traditional Chinese medicine formula for treating vital myocarditis | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN101647910B (en) | Traditional Chinese medicine for treating bronchial asthma | |
| CN103100007A (en) | Traditional Chinese medicine composition for treating human papilloma virus infection and preparation method and application thereof | |
| CN104524289A (en) | Medicine composition for treating wind-warm lung-heat diseases | |
| CN102335367B (en) | Medicine for treating pelvic inflammation | |
| CN102133369B (en) | Traditional Chinese medicine composition for treating acute cholecystitis | |
| CN104491546A (en) | Application of pharmaceutical composition in preparation of medicine for treating wind-warm lung-heat disease | |
| CN105327171A (en) | Traditional Chinese medicine electuary for treating mastitis and preparing method thereof | |
| CN105267372A (en) | Traditional Chinese medicine granule for treating postoperative gastrointestinal dysfunction and its preparation method | |
| CN104288681A (en) | Traditional Chinese medicine composition for treating children virus pneumonia | |
| CN104547610A (en) | Medicine composition for treating community acquired pneumonia | |
| CN103656353B (en) | A kind of pharmaceutical composition and application thereof for the treatment of pulmonary abscess | |
| CN102552767A (en) | Traditional Chinese medicine for treating kidney stone, preparation method and administration mode | |
| CN102824594B (en) | Traditional Chinese medicine for treating vital myocarditis | |
| CN102836403B (en) | Chinese medicine for treating chronic nephritis by using root of low greenbrier | |
| CN106038959A (en) | Traditional Chinese medicine composition for treating pneumonia and preparation method thereof | |
| CN104491369B (en) | Medicinal composition for treating hemoptysis | |
| CN105194588A (en) | Traditional Chinese medicine preparation for treating liver cirrhosis | |
| CN104491440A (en) | Application of pharmaceutical composition in preparing medicine for treating community-acquired pneumonia | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof | |
| CN105079580A (en) | Traditional Chinese medicine composition for treating wind-warm lung-heat disease | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| CN102940792A (en) | Traditional Chinese medicine composition for treating wind-warm syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150408 |
|
| RJ01 | Rejection of invention patent application after publication |